ORIC Pharmaceuticals, Inc. (ORIC)

NASDAQ: ORIC · IEX Real-Time Price · USD
9.80
-0.20 (-2.00%)
Apr 12, 2024, 4:00 PM EDT - Market closed
-2.00%
Market Cap 660.28M
Revenue (ttm) n/a
Net Income (ttm) -100.70M
Shares Out 67.38M
EPS (ttm) -1.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 306,137
Open 9.90
Previous Close 10.00
Day's Range 9.60 - 10.02
52-Week Range 4.89 - 16.65
Beta 1.03
Analysts Buy
Price Target 21.33 (+117.65%)
Earnings Date May 6, 2024

About ORIC

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2020
Employees 100
Stock Exchange NASDAQ
Ticker Symbol ORIC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ORIC stock is "Buy." The 12-month stock price forecast is $21.33, which is an increase of 117.65% from the latest price.

Price Target
$21.33
(117.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus comp...

5 days ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...

8 days ago - GlobeNewsWire

ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

9 days ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studie...

4 weeks ago - GlobeNewsWire

ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

5 weeks ago - GlobeNewsWire

ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

5 weeks ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address ...

6 weeks ago - GlobeNewsWire

ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanis...

2 months ago - GlobeNewsWire

ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

Funding from new and existing investors including Viking Global Investors, Commodore Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), and Nextech

2 months ago - GlobeNewsWire

ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

Initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer demonstrates potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated sa...

3 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

3 months ago - GlobeNewsWire

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients

4 months ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Presented initial Phase 1b data for ORIC-114 in patients with EGFR and HER2 Exon 20 mutated NSCLC demonstrating potential best-in-class profile

5 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

5 months ago - GlobeNewsWire

Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases

6 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and potential of ORIC-114 in EGFR/HER2 mutated cancers ...

6 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

7 months ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023

8 months ago - GlobeNewsWire

You can still run with the stock market's bulls, but watch the exits

The stock market, as measured by the S&P 500 Index SPX, -0.64%), has been moving upward. The U.S. benchmark index is essentially crawling up the higher “modified Bollinger Bands” (mBB), which is a bi...

Other symbols: CCLCRONEEMEWKOPNPFGPRU
9 months ago - Market Watch

ORIC Pharmaceuticals Announces $85 Million Private Placement Financing

Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital

10 months ago - GlobeNewsWire

ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address m...

11 months ago - GlobeNewsWire

ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023:  ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

1 year ago - GlobeNewsWire

ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 25, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

1 year ago - GlobeNewsWire

ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...

1 year ago - GlobeNewsWire

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates

Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023:  ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer

1 year ago - GlobeNewsWire